AZ pulls plug on Phase II asthma trial
AstraZeneca has called time on a mid-stage trial assessing an experimental inhaled interferon beta licensed from Southampton, UK-based group Synairgen.
Read More
Tag: AZD9412
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
